Jump to ContentJump to Main Navigation

Journal of Perinatal Medicine

Official Journal of the World Association of Perinatal Medicine

Editor-in-Chief: Dudenhausen, Joachim W.

Editorial Board Member: / Bancalari, Eduardo / Greenough, Anne / Genc, Mehmet R. / Chervenak, Frank A. / Chappelle, Joseph / Bergmann, Renate L. / Bernardes, J.F. / Bevilacqua, G. / Blickstein, Isaac / Cabero Roura, Luis / Carbonell-Estrany, Xavier / Carrera, Jose M. / D`Addario, Vincenzo / D'Alton, MD, Mary E. / Dimitrou, G. / Grunebaum, Amos / Hentschel, Roland / Köpcke, W. / Kawabata, Ichiro / Keirse, M.J.M.C. / Kurjak M.D., Asim / Lee, Ben H. / Levene, Malcolm / Lockwood, Charles J. / Marsal, Karel / Makatsariya, Alexander / Nishida, Hiroshi / Papp, Zoltán / Pejaver, Ranjan Kumar / Pooh, Ritsuko K. / Romero, Roberto / Saugstad, Ola D. / Schenker, Joseph G. / Sen, Cihat / Seri, Istvan / Vetter, Klaus / Winn, Hung N. / Young, Bruce K. / Zimmermann, Roland

6 Issues per year


IMPACT FACTOR 2014: 1.358
5-year IMPACT FACTOR: 1.597

SCImago Journal Rank (SJR) 2014: 0.731
Source Normalized Impact per Paper (SNIP) 2014: 0.687
Impact per Publication (IPP) 2014: 1.483

VolumeIssuePage

Issues

Immediate clinical outcomes in preterm neonates receiving antenatal magnesium for neuroprotection

Sudeepta Kumar Basu1 / Vijay Chickajajur1 / Vivian Lopez1 / Alok Bhutada1 / Murali Pagala2 / 1

1Division of Neonatology, Maimonides Infants and Children's Hospital of Brooklyn, Brooklyn, NY, USA

2Office of Health Science and Research, Maimonides Medical Center, Brooklyn, NY, USA

Corresponding author: Shantanu Rastogi, MD, MMM Associate Professor of Clinical Pediatrics SUNY-HSC at Brooklyn Attending Neonatologist Maimonides Infants and Children Hospital 1048 Tenth Avenue G-103 Brooklyn NY 11203 USA Tel.: +1-718-283-8853

Citation Information: Journal of Perinatal Medicine. Volume 40, Issue 2, Pages 185–189, ISSN (Online) 1619-3997, ISSN (Print) 0300-5577, DOI: 10.1515/jpm.2011.094, August 2011

Publication History

Received:
2011-06-28
Accepted:
2011-06-30
Published Online:
2011-08-11

Abstract

Background: Antenatal magnesium sulfate can potentially reduce the risk of cerebral palsy in neonates delivered between 24 and 32 weeks of gestational age. Some studies using high-dose magnesium sulfate for neuroprotection have reported increased perinatal mortality.

Methods: A retrospective study was conducted on 475 neonates born between 24 and 32 weeks of gestational age. Serum magnesium level in the first 24 h of life was used to stratify the neonates treated with antenatal magnesium into four subgroups: A (<2.5 mEq/L), B (≥2.5 to <3.5 mEq/L), C (≥3.5 to <4.5 mEq/L), and D (≥4.5 mEq/L). Primary outcome of survival without intraventricular hemorrhage (IVH) and/or periventricular leukomalacia (PVL) along with secondary outcomes, such as Apgar scores, resuscitation, intubation, broncho-pulmonary dysplasia, retinopathy of prematurity (ROP), patent ductus arteriosus (PDA), time to reach full feeds, length of stay (LOS), and mortality during immediate neonatal period were studied.

Results: Of the 475 neonates included in the study, 289 (61%) received antenatal magnesium sulfate. Primary outcome of survival without IVH and/or PVL among the preterm neonates was 70.9% in those receiving and 74.2% in those not receiving antenatal magnesium (P=0.25). There were higher incidences of ROP (P=0.02), PDA (P=0.01), greater time to reach full feeds (P=0.03), and increased LOS (P=0.01) in neonates who had received antenatal magnesium. These findings were not statistically significant when the data were corrected for gestational age and birth weight. Among the subgroups, there was a significantly increased mortality rate (P<0.05) with increasing magnesium levels (5% vs. 16.9%, P<0.05 in groups A vs. D) and a trend toward higher intubation rate (P=0.1) and PDA (P=0.14).

Conclusion: Antenatal magnesium is safe in the immediate postnatal period; however, in the subset of preterm neonates with serum magnesium levels >4.5 mEq/L, there is increased mortality independent of birth weight and gestational age. Identification of these neonates and appropriate dosing for their antenatal neuroprotection needs to be studied.

Keywords: Magnesium; mortality; neuroprotection; outcomes; preterm neonates

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Daphnie Drassinower, Alexander M. Friedman, Heather Levin, Sarah G. Običan, and Cynthia Gyamfi-Bannerman
American Journal of Obstetrics and Gynecology, 2015
[2]
D. E. Weisz, S. Shivananda, E. Asztalos, W. Yee, A. Synnes, S. K. Lee, and P. S. Shah
Archives of Disease in Childhood - Fetal and Neonatal Edition, 2015, Volume 100, Number 1, Page F59
[3]
Elizabeth Doll, Jacob Wilkes, Lawrence J. Cook, E. Kent Korgenski, Roger G. Faix, Bradley A. Yoder, Rajendu Srivastava, Catherine M. T. Sherwin, Michael G. Spigarelli, Erin A. S. Clark, and Joshua L. Bonkowsky
Frontiers in Pediatrics, 2014, Volume 2
[4]
Praveen Ballabh
Clinics in Perinatology, 2014, Volume 41, Number 1, Page 47
[5]
Kimberly A. Allen
Advances in Neonatal Care, 2013, Volume 13, Number 2, Page 127
[6]
Etsuko Shimada, Masaki Ogawa, Yoshio Matsuda, Minoru Mitani, and Hideo Matsui
Journal of Maternal-Fetal and Neonatal Medicine, 2013, Volume 26, Number 3, Page 270

Comments (0)

Please log in or register to comment.